Jay Cross
Chief Financial OfficerMr. Jay Cross is Chief Financial Officer of Senti Biosciences Holdings, Inc. (formerly known as Senti Biosciences, Inc.) from March 3, 2025. Mr. Cross joined the Senti Biosciences Holdings, Inc. (formerly known as Senti Biosciences, Inc.) on March 3, 2025. Mr. Jay Cross served as Chief Financial Officer at Sonnet BioTherapeutics Holdings, Inc. since May 2019 until February 21, 2025. He joined Sonnet BioTherapeutics Holdings, Inc. in May 2019 and served as its Chief Business Officer since May 2019. Mr. Cross was a Managing Director with Chardan Capital?s healthcare investment banking team from November 2015 to March 2019, where he focused on biopharmaceuticals. Mr. Cross worked as an analyst and portfolio manager specializing in therapeutics for several global institutional investment firms since 2002 until 2014. From May 2014 to June 2015, Mr. Cross served as a Director with Alere Financial Partners and from May 2011 to October 2013 as a Senior Analyst at Balyasny Asset Management. He launched his career in finance in 1999 as an associate analyst covering biotechnology on the healthcare equity research team at Hambrecht & Quist. Mr. Cross launched his career in finance covering biotechnology for the equity research divisions at Goldman Sachs. Mr. Cross earned a Master of Public Health from the Yale University School of Medicine and a Bachelor of Science in psychology from Washington & Lee University.
Positions
- Company NameSenti Biosciences Holdings, Inc.Stock CodeSNTIPositionChief Financial OfficerColleagues
- TKTimothy K. LuCo-Founder, CEO & Director
- KRKanya RajangamPresident, Head of Research & Development and Chief Medical Officer
- JJJames J. CollinsScientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director
- FSFaraz SiddiquiSenior Vice President of Technical Operations
- FDFrances D. SchulzIndependent Director
- MAMichael AndreeffMember of Scientific Advisory Board
- MKMichael KalosMember of Scientific Advisory Board
